Dynamic imaging markers of incident microhemorrhages and superficial siderosis in the A4 study: A longitudinal person-interval analysis
Hill C, Morgan H, Michopoulou S, Niranjan M and Kipps CM
Dynamic imaging markers of incident microhemorrhages and superficial siderosis in the A4 study: A longitudinal person-interval analysis
Hill C, Morgan H, Michopoulou S, Niranjan M and Kipps CM
Incident microhemorrhages and superficial siderosis are hemorrhagic magnetic resonance imaging (MRI) abnormalities relevant to amyloid-related imaging abnormalities with hemosiderin deposition (ARIA-H) risk stratification, but evidence exploring their short-term dynamic predictors remains limited.
Mixed-methods feasibility study of a community-based model to improve equity and efficiency in dementia research participation: protocol for ACCESS D
Fuller P, Claxton A, Pocock H, Williams SJ, Claxton N, Wollam A, Blackburn D, Devitt G, Fearn S and Kipps C
Mixed-methods feasibility study of a community-based model to improve equity and efficiency in dementia research participation: protocol for ACCESS D
Fuller P, Claxton A, Pocock H, Williams SJ, Claxton N, Wollam A, Blackburn D, Devitt G, Fearn S and Kipps C
Despite national efforts to improve research inclusion, people from underserved communities remain underrepresented in dementia trials. Barriers occur at the point of initial engagement and also within the participation pathway itself, as the structure and burden of early screening procedures can discourage continuation. ACCESS D (Advancing Community Collaboration and Engagement Strategies in Dementia) aims to address these challenges by testing a community-based model that combines co-produced engagement events, low-burden research participation, and real-time support from the South Central Ambulance Service (SCAS), a trusted, community-visible National Health Service (NHS) healthcare workforce serving the counties of Hampshire, Oxfordshire, Buckinghamshire and Berkshire in Southern England, UK.
Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507]
Perry R, Kipps C, Martín MES, Bozzali M, Logroscino G, Trafford S, Dhadda S, Kanekiyo M, Goodwin A, Hodgkinson M, Hersch S, Irizarry M, Kramer L and Froelich L
Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507]
Perry R, Kipps C, Martín MES, Bozzali M, Logroscino G, Trafford S, Dhadda S, Kanekiyo M, Goodwin A, Hodgkinson M, Hersch S, Irizarry M, Kramer L and Froelich L
REMOTE-Neuro: co-produced recommendations to optimise remote neurology
Fuller P, Fearn S, Dace S, Wollam A, Zarkali A, Cowan A, Mountney S, Carr G, Eriksson SH and Kipps C
REMOTE-Neuro: co-produced recommendations to optimise remote neurology
Fuller P, Fearn S, Dace S, Wollam A, Zarkali A, Cowan A, Mountney S, Carr G, Eriksson SH and Kipps C
To examine stakeholder experiences of remote neurology outpatient care and to co-produce an evidence-based framework to support safe, equitable and sustainable service delivery.
A real-world feasibility study: at home longitudinal use of the Cumulus NeuLogiq® platform for electrophysiological and neurocognitive measures in patients with mild Alzheimer's Disease dementia
Diggin S, Rueda-Delgado L, Buick A, Dyer JF, Alexander-Sefre A, Barbey F, Rowe JB, Muhammed K, Harel BT, Hansen BJ, Tunbridge E, Lai R, Hawellek DJ, Hake AM, Marston H, Oswal A, Coulthard E, Pattan V, Evans V, Gibson S, Kipps C, Kozak R, Mannering N, Moss M, Nguyen V, Ruddock K, Shinobu LA, Toniolo S and Murphy B
A real-world feasibility study: at home longitudinal use of the Cumulus NeuLogiq® platform for electrophysiological and neurocognitive measures in patients with mild Alzheimer's Disease dementia
Diggin S, Rueda-Delgado L, Buick A, Dyer JF, Alexander-Sefre A, Barbey F, Rowe JB, Muhammed K, Harel BT, Hansen BJ, Tunbridge E, Lai R, Hawellek DJ, Hake AM, Marston H, Oswal A, Coulthard E, Pattan V, Evans V, Gibson S, Kipps C, Kozak R, Mannering N, Moss M, Nguyen V, Ruddock K, Shinobu LA, Toniolo S and Murphy B
Dementias, including those caused by Alzheimer's Disease (AD), are a leading global cause of death, necessitating improvements in early detection and development of more effective disease-modifying therapies. Well-validated pen-and-paper measures serve as the primary method used for cognitive assessment in research and clinical trials in AD. However, these suffer from rater error, infrequent "snapshot" bias, and have limited sensitivity to early-stage pathology, which presents challenges for measuring efficacy in prevention trials. Recent technological advances offer the potential to measure subtle cognitive changes and account for day-to-day variability through real-world data collection. The Cumulus Neuroscience NeuLogiq® platform ("the platform"), is comprised of a wireless electroencephalography (EEG) headset, tablet-based cognitive tasks based on well-established paradigms which were designed to be user-friendly based on patient panel inputs, third party integrations (mood, speech and sleep assessments) and cloud-based analytics. This platform has demonstrated utility in healthy populations and may enable objective, frequent, and patient-centered disease tracking in AD and other CNS disorders.